Humana (HUM)
(Delayed Data from NYSE)
$247.26 USD
-2.61 (-1.04%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $247.14 -0.12 (-0.05%) 7:58 PM ET
4-Sell of 5 4
A Value C Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HUM 247.26 -2.61(-1.04%)
Will HUM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HUM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUM
Why Humana (HUM) is a Top Momentum Stock for the Long-Term
HUM Misses Q2 Earnings on Higher Benefit Costs, Ups '25 EPS View
HUM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's What Key Metrics Tell Us About Humana (HUM) Q2 Earnings
CVS Health Care Delivery: Will the Growth Momentum Last in Q2?
Humana (HUM) Q2 Earnings Lag Estimates
Other News for HUM
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Barclays Raises Price Target for Humana (HUM) to $275 | HUM Stock News
Humana (HUM) Target Price Lowered by Morgan Stanley | HUM Stock News
Humana (HUM) Expands Cancer Screening Accessibility with New Partnership
Humana (HUM) Target Price Reduced by Piper Sandler